Application of microRNA-455-5p in preparation of kit for detecting broiler limb ectropion and ectropion deformity

By applying microRNA-455-5p in the limb valgus deformity kit of broiler limbs, it clarifies its high expression and regulatory mechanism in cartilage tissue, solves the problem of abnormal growth and development of joint cartilage in broiler chickens, and provides new diagnostic and treatment ideas , improves the specificity and efficiency of broiler health management.

CN118995914AInactive Publication Date: 2024-11-22HENAN AGRICULTURAL UNIVERSITY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411116817.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and specifically detect abnormal growth and development of articular cartilage caused by valgus deformities in the limbs of broilers, affecting the growth and immune function of broilers.

Method used

Through the application of microRNA-455-5p (miR-455-5p) in the preparation and detection of valgus deformity kits for broiler limbs, it was clear that miR-455-5p is significantly high in cartilage tissues, and it was inhibited by inhibiting RPS6KB1 gene expression and RPS6 phosphate , inhibits the proliferation of articular chondrocytes, and provides targets for diagnosis and treatment.

Benefits of technology

The importance of miR-455-5p regulation axis for the development of cartilage in the valgus deformed joints of broiler limbs was clarified, and new diagnostic and therapeutic ideas were provided, theoretical and experimental basis for the study of broiler leg disease, enriching the selection of targeted drugs. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995914A_ABST
    Figure CN118995914A_ABST
Patent Text Reader

Abstract

The invention discloses application of microRNA-455-5p in preparation of a kit for detecting broiler limb ectropion and ectropion deformity, belongs to the technical field of biological medicine, and provides application of the microRNA-455-5p in preparation of the kit for detecting broiler limb ectropion and ectropion deformity, and the nucleotide sequence of the microRNA-455-5p is as shown in SEQ ID NO.1. The invention further discloses application of the microRNA-455-5p in preparation of the kit for detecting broiler limb ectropion and ectropion deformity. The invention further provides a broiler limb ectropion and ectropion deformity detection kit with the microRNA-455-5p as the diagnostic marker. According to the invention, abnormal development of articular cartilage of broiler chickens with limb ectropion and ectropion deformity is proved, and obvious high expression of miR-455-5p in cartilage tissues is clear; it is proved that miR-455-5p reduces the phosphorylation level of RPS6 by inhibiting the target gene RPS6KB1 of miR-455-5p, and further inhibits the growth and development of cartilage.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of microRNA-455-5p in preparing a kit for detecting varus-valgus deformity of limbs in broiler chickens. Background Art

[0002] Due to the intensive breeding of broilers, leg diseases have become an important factor endangering the growth and development, economic benefits and animal welfare of broilers. Common leg diseases in broilers include femoral head necrosis (FHN), tibial dyschondroplasia (TD) and valgus-varus deformity (VVD).

[0003] FHN mainly occurs in the late stage of breeding. Its typical anatomical feature is the decrease in subchondral bone resistance in the late stage of broiler breeding. The cartilage of the entire femoral head is like a hat and often falls off. The pathological feature of TD is the obvious avascular and unmineralized area in the proximal growth plate cartilage tissue of the tibia and tarsus. The cause of the disease is often environmental toxins, drugs and heavy metals. VVD is a broiler leg deformity with complex etiology. It was originally called "leg twist" and later corrected to valgus and valgus deformity of the limbs. Its main feature is the valgus (outward angle) or valgus (inward angle) of a certain angle of bilateral or unilateral tibial pedicles and tarsometatarsals. This deformed walking posture can cause damage and abnormal development of the leg bone structure, which in turn affects the overall physiological and biochemical state, reduces immune function, and increases vulnerability to external environmental factors (such as bacterial infection).

[0004] The growth and development of long bones mainly depends on endochondral ossification. Abnormal development of cartilage growth plates is one of the most important injury processes in leg diseases. A large number of studies have confirmed that TD and FHN broiler cartilage tissues have abnormal development, such as less vascular invasion, dysplasia, mineralization disorders, disordered chondrocyte arrangement and apoptosis. And preliminary studies have found that VVD broilers have sparse trabeculae, reduced long bone strength, and contain white non-mineralized areas. However, the histopathological changes and growth status of the growth plate cartilage of VVD broilers remain unclear.

[0005] Generally speaking, the detection of cartilage tissue in leg diseases mainly relies on staining technology and electron microscopy technology. Common staining methods include HE staining, safranin fast green staining, toluidine blue staining and alcian blue staining. These methods can distinguish between cartilage tissue and osteoblastic tissue. Combined with electron microscopy technology, certain pathological changes can be found. However, the cumbersomeness of making cartilage tissue sections and the cost of electron microscopy are the main factors affecting its development. Therefore, considering the convenience, breadth and specificity, these two methods still have certain defects. There is still a need for a highly specific and rapid method to clarify the abnormal growth and development of articular cartilage in leg diseases.

[0006] Exosomes are a typical extracellular vesicle that can be secreted by most cells in the body. They are approximately 30-150nm in diameter and are widely distributed. They can be found in different biological fluids, including blood, exudate, saliva, ascites, milk and urine. They mainly contain mRNA, microRNA (miRNA), proteins and a small amount of DNA molecules, which are transported to target cells through circulating body fluids to play the role of intercellular communication. Among them, miRNA is one of the most thoroughly studied molecules. MiRNA can regulate the growth and development of the body by acting on its target genes. MiR-455 is a widely conserved member of the miRNA family. According to the different processing of the 5' end arm and the 3' end arm of the mir-455 precursor, it is divided into miR-455-5p and miR-455-3p. Early studies have shown that miR-455-5p / 3p is highly expressed in articular cartilage tissue and chondrocytes, and can be upregulated by SOX9. Both target HIF-2α and regulate cartilage homeostasis; miR-455-5p can alleviate tension-induced endplate chondrocyte degeneration by targeting and inhibiting RUNX2 expression. However, the research on miR-455-5p in varus and valgus deformity of broiler limbs is currently blank. It is the research focus of this invention to clarify how miR-455-5p regulates the development of articular cartilage in varus and valgus deformity of broiler limbs. Summary of the invention

[0007] In order to solve the above technical problems, the present invention proposes the use of microRNA-455-5p (miR-455-5p) in the preparation of a kit for detecting varus-valgus deformity of broiler limbs. The present invention confirms the abnormal development of articular cartilage in broiler limbs with varus-valgus deformity, and clarifies that miR-455-5p is significantly highly expressed in cartilage tissue; and it is found that plasma exosomes can transmit miR-455-5p to regulate cartilage growth and development, and it is found that miR-455-5p reduces the phosphorylation level of RPS6 by inhibiting its target gene RPS6KB1, thereby inhibiting cartilage growth and development, and it is found that miR-455-5p and its regulatory axis are of great significance to the regulation of articular cartilage with varus-valgus deformity of broiler limbs.

[0008] To achieve the above object, the present invention provides the use of microRNA-455-5p in preparing a kit for detecting broiler limb valgus and valgus deformity, wherein the nucleotide sequence of the microRNA-455-5p is shown in SEQ ID NO.1.

[0009] Preferably, the microRNA-455-5p inhibits the expression of RPS6KB1 gene, inhibits RPS6 phosphorylation, and further inhibits the synthesis of type II collagen and the proliferation of articular chondrocytes.

[0010] Preferably, the nucleotide sequence of the RPS6KB1 gene is shown in SEQ ID NO.2.

[0011] The present invention also provides a broiler limb valgus and valgus deformity detection kit using the microRNA-455-5p as a diagnostic marker.

[0012] The present invention also provides the use of the microRNA-455-5p in preparing the RPS6KB1 gene expression inhibitor.

[0013] The present invention also provides a RPS6KB1 gene expression inhibitor, which includes microRNA-455-5p.

[0014] The present invention also provides the use of the microRNA-455-5p in preparing an articular chondrocyte proliferation inhibitor.

[0015] The present invention also provides an articular chondrocyte proliferation inhibitor, which comprises microRNA-455-5p.

[0016] The present invention also provides an application of a reagent for inhibiting the expression of the microRNA-455-5p in preparing a reagent for treating broiler limb valgus and valgus deformity.

[0017] The present invention also provides an application of a reagent for inhibiting the expression of microRNA-455-5p in the preparation of an articular chondrocyte proliferation promoter.

[0018] Compared with the prior art, the present invention has the following advantages and technical effects:

[0019] The present invention, by clarifying that broilers with valgus and varus deformities have abnormal development of articular cartilage, combined with the key miR-455-5p in plasma exosomes in the previous period, fundamentally explored the specific mechanism of miR-455-5p in regulating abnormal development of articular cartilage, and clarified the potential value of the miR-455-5p regulatory axis in coping with abnormal development of articular cartilage in broilers with valgus and varus deformities. The present invention discloses for the first time the growth characteristics of articular cartilage in broilers with valgus and varus deformities and the miR-455-5p regulatory axis, providing new ideas for enriching the research on broiler leg diseases, and providing theoretical and experimental basis for further treatment of broiler leg diseases and the selection of new targeted drugs for research and development. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 The tibia and metatarsal bones of broiler chickens in the diseased and healthy groups were stained with safranin fast green. In the figure, VVD represents the diseased group and Normal represents the healthy group.

[0022] Figure 2 This is a graph showing the growth status of chondrocytes in diseased and healthy groups of broiler chickens. In the figure, VVD represents the diseased group and Normal represents the healthy group.

[0023] Figure 3 The statistical graphs of gene expression related to chondrocyte proliferation in diseased and healthy groups of broiler chickens detected by qPCR, where A is the statistical graph of gene expression related to chondrocyte proliferation in primary diseased and healthy groups, and B is the statistical graph of gene expression related to chondrocyte proliferation in F1 generation diseased and healthy groups;

[0024] Figure 4 The expression statistics of genes related to cartilage tissue proliferation in diseased and healthy broiler chickens detected by qPCR, where A is the expression statistics of genes related to proliferation in cartilage tissue in diseased and healthy broiler chickens, and B is the intracellular DNA content at different stages of the cell cycle of chondrocytes in diseased and healthy groups detected by flow cytometry;

[0025] Figure 5 The statistical diagram of the cell cycle of chondrocytes in diseased and healthy groups of broiler chickens detected by flow cytometry, wherein A is the statistical diagram of the cell cycle of chondrocytes in diseased group of broiler chickens, and B is the statistical diagram of the cell cycle of chondrocytes in healthy group of broiler chickens;

[0026] Figure 6 This is a picture of chondrocytes taking up plasma exosomes, where A is DAPI-labeled nucleus, B is rhodamine-coupled phalloidin-labeled cytoskeleton, C is PKH67-labeled exosomes, D is a merged picture of A, B, and C, and E is a 20X magnification of the merged picture;

[0027] Figure 7 This is the optimal concentration determination diagram for plasma exosomes to treat chondrocytes;

[0028] Figure 8This is a statistical graph of plasma exosomes regulating the expression of miR-455-5p in chondrocytes and the inhibition experiment. In the figure, PBS represents the control group with the addition of equal amount of PBS, Nor-exos represents the addition of plasma exosomes from healthy broiler chickens, VVD-exos represents the addition of plasma exosomes from diseased broiler chickens, Nor-exos-inhibitors represents the addition of plasma exosomes from healthy broiler chickens and miR-455-5p-inhibitors, VVD-exos-inhibitors represents the addition of plasma exosomes from diseased broiler chickens and miR-455-5p-inhibitors, Nor-exos-inhibitorsNC represents the NC control with the addition of plasma exosomes from healthy broiler chickens and miR-455-5p-inhibitors, and VVD-exos-inhibitorsNC represents the NC control with the addition of plasma exosomes from diseased broiler chickens and miR-455-5p-inhibitors;

[0029] Fig. 9 This is a statistical diagram of the inhibition of chondrocyte proliferation by plasma exosomes. In the figure, PBS represents the control group, Nor-exos represents the addition of plasma exosomes from healthy broiler chickens, VVD-exos represents the addition of plasma exosomes from diseased broiler chickens, Nor-exos-inhibitors represents the addition of plasma exosomes from healthy broiler chickens and miR-455-5p-inhibitors, VVD-exos-inhibitors represents the addition of plasma exosomes from diseased broiler chickens and miR-455-5p-inhibitors, Nor-exos-inhibitorsNC represents the NC control with the addition of plasma exosomes from healthy broiler chickens and miR-455-5p-inhibitors, and VVD-exos-inhibitorsNC represents the NC control with the addition of plasma exosomes from diseased broiler chickens and miR-455-5p-inhibitors;

[0030] Fig.10 This is the tissue expression profile of miR-455-5p in diseased and healthy broiler chickens. In the figure, VVD represents the diseased group and Normal represents the healthy group.

[0031] Fig.11 It is a statistical diagram of the overexpression / interference of miR-455-5p expression level. In the figure, mimics NC represents the control group overexpressing miR-455-5p, mimics represents the overexpression miR-455-5p group, inhibitors NC represents the control group interfering with miR-455-5p, and inhibitors represents the interfering miR-455-5p group;

[0032] Fig.12This is a statistical diagram of chondrocyte proliferation-related gene expression detected by qPCR overexpression / interference of miR-455-5p. In the figure, mimics / inhibitors NC represents the control group overexpressing / interfering with miR-455-5p, mimics represents the group overexpressing miR-455-5p, and inhibitors represents the group interfering with miR-455-5p;

[0033] Fig.13 This is a graph showing the expression of Collage 2, a chondrocyte proliferation-related protein detected by Western Blot in the group overexpressing / interfering with miR-455-5p. In the figure, mimicsNC represents the control group of the miR-455-5p overexpression group, mimics represents the miR-455-5p overexpression group, inhibitorsNC represents the control group of the miR-455-5p interference group, and inhibitors represents the miR-455-5p interference group;

[0034] Fig.14 Figure 3 is a graph showing the proliferation of chondrocytes after 36 hours of overexpression / interference of miR-455-5p by EDU, wherein A is a graph showing the proliferation of chondrocytes after overexpression of miR-455-5p and its NC control group, B is a graph showing the proliferation of chondrocytes after interference of miR-455-5p and its NC control group, C is the proliferation rate of chondrocytes after 36 hours of treatment with miR-455-5p overexpression and its control group, and D is the proliferation rate of chondrocytes after 36 hours of treatment with miR-455-5p interference and its control group. NC represents the control group with overexpression of miR-455-5p, mimics represents the group with overexpression of miR-455-5p, inhibitorsNC represents the control group with interference of miR-455-5p, inhibitors represents the group with interference of miR-455-5p, Hoechst33342 represents the nuclear stain of living cells, EDU represents a thymidine analogue that can replace thymine (T) and penetrate into the synthesizing DNA molecule during DNA replication, Marged represents the pattern merging process;

[0035] Fig.15 Figure 1 is a graph showing the proliferation of chondrocytes at different time points after overexpression / interference of miR-455-5p by CCK-8, wherein A is a graph showing the inhibition of chondrocyte proliferation at different time points after overexpression of miR-455-5p by CCK-8, and B is a graph showing the promotion of chondrocyte proliferation at different time points after interference of miR-455-5p by CCK-8;

[0036] Fig.16This is the expression graph of cell cycle-related genes in chondrocytes overexpressing / interfering with miR-455-5p detected by qPCR, wherein A is the expression graph of cell cycle-related genes in miR-455-5p overexpression and its control group, and B is the expression graph of cell cycle-related genes in miR-455-5p interference and its control group. In the figure, mimics NC represents the control group of miR-455-5p overexpression group, mimics represents the miR-455-5p overexpression group, inhibitorsNC represents the control group of miR-455-5p interference group, and inhibitors represents the miR-455-5p interference group;

[0037] Fig.17 The key RPS6KB1 map was located for the three target gene prediction sites;

[0038] Fig.18 Figure 2 shows the expression of RPS6KB1 gene in chondrocytes overexpressing / interfering with miR-455-5p detected by qPCR. In the figure, mimics NC represents the control group of the miR-455-5p overexpression group, mimics represents the miR-455-5p overexpression group, inhibitors NC represents the control group of the miR-455-5p interference group, and inhibitors represents the miR-455-5p interference group;

[0039] Fig.19 Explore the pathway map related to miR-455-5p target genes for KEGG;

[0040] Fig. 20 Map of the target sites of miR-455-5p and RPS6KB1;

[0041] Fig.21 The dual luciferase reporter experiment verifies the targeting relationship between miR-455-5p and RPS6KB1 in chondrocytes and chicken fibroblast cell lines, wherein A is a dual luciferase reporter experiment performed on chondrocytes to verify the targeting relationship, and B is a dual luciferase reporter experiment performed on chicken fibroblast cell lines to verify the targeting relationship. In the figure, miR-455-5p mimics represents the miR-455-5p overexpression group, miR-455-5p mimics NC represents the control group of the miR-455-5p overexpression group, Vector-Luc-RPS6KB1-WT-3'UTR represents the constructed wild-type vector of the RPS6KB1 gene, and Vector-Luc-RPS6KB1-MUT-3'UTR represents the constructed mutant vector of the RPS6KB1 gene;

[0042] Fig. 22This is a diagram of siRPS6KB1 interference detected by qPCR, in which NC represents the control group of the siRPS6KB1 interference fragment treatment group, siRNA1 represents the siRPS6KB1 interference fragment 1 treatment group, siRNA2 represents the siRPS6KB1 interference fragment 2 treatment group, and siRNA3 represents the siRPS6KB1 interference fragment 3 treatment group;

[0043] Fig.23 This is a graph showing the proliferation of chondrocytes by detecting siRPS6KB1 with EDU, wherein A is a graph showing the effects of interference fragment 1 of the RPS6KB1 gene and its control group on the proliferation of chondrocytes, B is a fluorescence graph showing nuclear staining with Hoechst33342 in the siRPS6KB1 group, C is a fluorescence graph showing the siRPS6KB1 group after EDU reagent treatment, D is a combined graph showing nuclear staining with Hoechst33342 and treatment with EDU reagent in the siRPS6KB1 group, E is a fluorescence graph showing nuclear staining with Hoechst33342 in the siRPS6KB1NC group, F is a fluorescence graph showing the siRPS6KB1NC group after EDU reagent treatment, G is a combined graph showing nuclear staining with Hoechst33342 and treatment with EDU reagent in the siRPS6KB1NC group, in which siRNANC represents the control group of the siRPS6KB1 treatment group, and siRNA represents the siRPS6KB1 treatment group;

[0044] Fig.24 This is a graph of chondrocyte proliferation-related gene expression detected by qPCR with siRPS6KB1, in which siRNANC represents the control group of the RPS6KB1 gene interference fragment treatment group, and siRNA represents the RPS6KB1 gene interference fragment treatment group;

[0045] Fig.25 This is a diagram of Western Blot detection of siRPS6KB1 chondrocyte proliferation-related protein Collage 2, in which siRNANC represents the control group of the RPS6KB1 gene interference fragment treatment group, and siRNA represents the RPS6KB1 gene interference fragment treatment group;

[0046] Fig.26This is the expression diagram of Collage 2, a chondrocyte proliferation-related protein detected by Western Blot with siRPS6KB1, wherein A is the expression diagram of chondrocyte-related proteins after siRPS6KB1 treatment, NC represents the control group of siRPS6KB1 group, siRNA represents the siRPS6KB1 treatment group, B is the expression diagram of chondrocyte-related proteins in the miR-455-5p overexpression treatment group and its control group, NC represents the control group of miR-455-5p overexpression group, mimics represents the miR-455-5p overexpression group, C is the expression diagram of siRPS6KB1 treatment group and its control group, miR-455-5p mimics group and its control group, and miR-455-5p The protein band diagram of the expression of related proteins in chondrocytes treated with the inhibitors group and its control group, siRNANC represents the control group of the siRPS6KB1 group, siRNA represents the siRPS6KB1-treated group, mimicsNC represents the control group of the miR-455-5p overexpression group, mimics represents the miR-455-5p overexpression group, inhibitorsNC represents the control group of the miR-455-5p interference group, inhibitors represents the miR-455-5p interference group, D is the expression diagram of chondrocyte-related proteins in the miR-455-5p interference group and its control group, NC represents the control group of the miR-455-5p interference group, inhibitors represents the miR-455-5p interference group;

[0047] Fig. 27 This is a diagram showing the proliferation of chondrocytes at different time points after CCK-8 detection of siRPS6KB1. In the figure, siRNANC represents the control group of the siRPS6KB1-treated group, and siRNA represents the siRPS6KB1-treated group. DETAILED DESCRIPTION

[0048] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0049] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0050] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0051] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0052] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0053] Example

[0054] 1. In vitro and in vivo functional experiments on articular cartilage of chicken limbs with valgus deformity

[0055] 1. Safranin Fast Green Staining of Articular Cartilage in Broiler Limbs with Valgus and Valgus Deformity

[0056] In this example, three 2-week-old VVD (Score=3) and normal broilers were randomly selected, and the tibia and metatarsal joint growth plates were collected in 4% paraformaldehyde. After 2 days, they were decalcified, embedded in paraffin, sliced, permeabilized with xylene, treated with fast green and safranin staining solutions, dehydrated with gradient ethanol, and sealed with optical resin. Scanning was performed using a scanner.

[0057] The results showed that compared with the healthy group, the tibial and metatarsal growth plates in the VVD group had less blood vessel enrichment, thinner proliferation zones, fewer differentiated osteoblasts, and delayed calcification. Histopathological examination showed that the chondrocytes in the hypertrophic zone of the growth plate in the normal group were relatively dense and compact, with a relatively regular structure, while the chondrocytes in the hypertrophic zone of the VVD growth plate were disordered, and most chondrocytes showed vacuolar nuclear condensation and nucleolar dissolution (such as Figure 1 shown).

[0058] 2. Gene expression of proliferation and differentiation of articular cartilage in varus-valgus deformity of broiler limbs

[0059] RNA was extracted from articular cartilage and reverse transcribed into cDNA after concentration determination. The expression of proliferation and differentiation genes Collage2, ALP and RUNX2 was detected by qPCR, and the data were analyzed by relative quantification.

[0060] Table 1 qPCR detection gene primer information

[0061]

[0062] Note: F is the upstream primer, R is the downstream primer.

[0063] The results showed that compared with the healthy group, the cartilage proliferation and differentiation-related genes Collage 2, ALP and RUNX2 in the VVD group were significantly downregulated (e.g. Figure 4 A and B in the figure).

[0064] 3. Cell cycle of chondrocytes in varus-valgus deformity of broiler limbs

[0065] Observe and record the growth of chondrocytes in the healthy group and VVD group. When the chondrocytes in the six-well plate of the healthy group grow to 90%, wash the cells with PBS 1-2 times, digest with trypsin, fix with 75% cold ethanol, and stain with the pre-prepared PI / RNaseA staining working solution at room temperature and away from light for 30-60 minutes. Record the red fluorescence value at the excitation wavelength of 488nm.

[0066] The results showed that the growth and proliferation of chondrocytes in the VVD group were slower than those in the healthy group (e.g. Figure 2 As shown in Figure 2, the expression of marker genes and abnormal changes in cell cycle. When the cells in the healthy group grew to 90% and entered the cell cycle, the proportion of F2 chondrocytes in the S phase of the VVD group was significantly higher than that in the healthy group, and the proportion of G1 and G2 phases was significantly lower than that in the healthy group (P<0.01) (as shown in Figure 2). Figure 5 A and B in the figure).

[0067] 4. Gene expression of proliferation and differentiation of chondrocytes in broiler chicken limbs with inside-out valgus deformity

[0068] When the cells in the healthy group grew to 90%, RNA of articular chondrocytes in the two groups was extracted and reverse transcribed into cDNA after concentration determination. qPCR was used to detect the expression of proliferation and differentiation genes Collage 2, ACAN and Pthrp, and the data were analyzed using relative quantification.

[0069] The results showed that the proliferation-related gene Collage 2 in the VVD group was significantly upregulated, indicating that while the chondrocytes in the healthy group were in the stable growth phase, the chondrocytes in the VVD group were only in the logarithmic growth phase (e.g. Figure 3 Middle A and Figure 3 (shown in B).

[0070] II. Tissue expression profile of miR-455-5p in broiler limb valgus deformity

[0071] The inventors randomly selected 15 2-week-old VVD (Score = 3) and normal broilers, and collected their heart, liver, spleen, kidney, breast muscle, leg muscle, duodenum, cartilage, bursa of Fabricius and thymus tissues and stored them at -80 ° C. RNA from each tissue was extracted and reverse transcribed into cDNA, and qPCR was used to detect the expression of miR-455-5p in each tissue. U6 was the internal reference of miRNA in qPCR verification, and the data were analyzed using relative quantification.

[0072] The nucleotide sequence of miR-455-5p, SEQ ID NO.1: UAUGUGCCCUUGGACUACAUCG.

[0073] The results showed that miR-455-5p was expressed in the liver, kidney, duodenum and cartilage. Among them, the expression level in cartilage was significantly higher than that in other tissues, about 1200 times. In addition, the expression of cartilage tissue in the healthy group and the VVD group was compared, and it was found that the miR-455-5p in the VVD group was significantly higher than that in the healthy group (such as Fig.10 shown).

[0074] Table 2 miRNA primer information

[0075]

[0076] Note: F is the upstream primer, R is the downstream primer, and Q is the reverse transcription primer.

[0077] 3. Plasma exosomes deliver miR-455-5p to regulate chondrocyte proliferation

[0078] The chondrocytes were treated with plasma exosomes from diseased and healthy broilers, and PBS was used as the control group. PKH67 labeled plasma exosomes, DAPI labeled cell nuclei, and phalloidin labeled cytoskeleton. Combined with qPCR, the optimal concentration of exosomes was explored in different groups. qPCR was used to detect the expression of miR-455-5p and chondrocyte proliferation-related genes Collage 2, MMP9, and MMP13 in the experimental group.

[0079] The results showed that the fluorescence uptake experiment proved that plasma exosomes can be taken up by chondrocytes (e.g. Figure 6 Middle A, Figure 6 Middle B, Figure 6 Middle C, Figure 6 Medium D and Figure 6 E), and the optimal concentration of exosomes for treatment was 7 μg / mL (as shown in Figure 7 qPCR results showed that plasma exosomes changed the expression of miR-455-5p in chondrocytes and could be inhibited by miR-455-5p-inhibitors (as shown in Figure 8); significantly down-regulated the expression of Collage 2 and MMP9 genes, and significantly up-regulated the expression of MMP13 gene (as shown in Fig. 9 It was shown that it inhibited the proliferation of chondrocytes and destroyed the homeostasis of chondrocytes.

[0080] 4. miR-455-5p regulates chondrocyte proliferation

[0081] 1. miR-455-5p-mimics inhibits chondrocyte proliferation

[0082] RNA was extracted from heart, liver, spleen, kidney, pectoral muscle, leg muscle, duodenum, cartilage, bursa of Fabricius and thymus tissues and reverse transcribed into cDNA. The expression of miR-455-5p in each tissue was detected by qPCR, and the data were analyzed by relative quantification.

[0083] Results Fig.10 It was found that miR-455-5p was highly expressed in the liver, spleen, kidney, duodenum, and cartilage tissues, and was significantly higher in cartilage tissue than in other tissues. The VVD group was significantly higher than the healthy group, followed by the duodenum, liver, and kidney.

[0084] Chondrocytes were treated with miR-455-5p-mimics and its NC, and CCK-8 was used to detect the proliferation rate of chondrocytes at different time points; EDU was used to detect the proliferation status of chondrocytes after 36 hours of treatment; qPCR was used to detect the expression of proliferation and metabolism-related genes Collage2, MMP9 and MMP13 and cell cycle-related genes after 36 hours of treatment; Western Blot focused on detecting the expression of Collage 2 protein.

[0085] NC treatment: F1 chondrocytes were cultured at 5 × 10 5 The cells were cultured in a 12-well plate at a density of 100 μg / mL. After overnight culture, the empty plasmid (i.e., miR-455-5p mimicsNC, dry powder) was diluted to a certain concentration using sterile enzyme-free water according to the instructions. The concentration was 50 nM as found in the preliminary experiments, and liposome transfection of chondrocytes was performed.

[0086] The results showed that miR-455-5p-mimics significantly upregulated the expression of miR-455-5p in chondrocytes (e.g. Fig.11 The results of CCK-8 and EDU showed that it significantly inhibited the proliferation of chondrocytes at different time points (as shown in Fig.14 In A, such as Fig.15 Middle A and Fig.16 qPCR results showed that the expression of Collage 2, MMP9 and MMP13 genes were significantly downregulated (as shown in Fig.12); Western Blot results showed that the expression of Collage 2 protein was significantly downregulated (as shown in Fig.13 The combined results showed that miR-455-5p-mimics inhibited chondrocyte proliferation.

[0087] 2. miR-455-5p-inhibitors promote chondrocyte proliferation

[0088] Chondrocytes were treated with miR-455-5p-inhibitors and their NCs, and CCK-8 was used to detect the proliferation rate of chondrocytes at different time points. EDU was used to detect the proliferation status of chondrocytes after 36 h of treatment. qPCR was used to detect the expression of proliferation and metabolism-related genes Collage 2, MMP9 and MMP13 and cell cycle-related genes after 36 h of treatment. Western Blot focused on detecting the expression of Collage 2 protein.

[0089] The results showed that miR-455-5p-inhibitors significantly downregulated the expression of miR-455-5p in chondrocytes (e.g. Fig.11 The results of CCK-8 and EDU showed that it significantly promoted the proliferation of chondrocytes at different time points (as shown in Fig.14 In B, such as Fig.16 Medium B and Fig.15 qPCR results showed that the expression of Collage 2 and MMP9 genes were significantly upregulated (Fig. Fig.12 ); Western Blot results showed that the expression of Collage2 protein was significantly upregulated (as shown in Fig.13 The combined results showed that miR-455-5p-inhibitors promoted chondrocyte proliferation.

[0090] from Fig.14 Middle C and Fig.14 As shown in D, the cell proliferation rate of the miR-455-5p overexpression group was significantly reduced compared with the control mimics NC group, indicating that overexpression of miR-455-5p inhibited cell proliferation, while interference had the opposite effect.

[0091] 5. Confirmation of the targeting relationship between miR-455-5p and RPS6KB1

[0092] Combined with the miRNA database and NCBI database to query the target sites of miR-455-5p and RPS6KB1, two pairs of 300-400bp DNA single strands were designed with the RPS6KB1 target site and mutation site. The PSIcheck2 vector was linearized with the noti and xhol sites, and homologous recombination was used to combine with the designed DNA single strand to construct WT-RPS6KB1-3'UTR and Mut-RPS6KB1-3'UTR recombinant plasmids. The nucleotide sequence of the RPS6KB1 gene is shown in SEQ ID NO.2.

[0093] According to the grouping instructions of the Lip3000 manufacturer, chondrocytes were transfected with the constructed WT / Mut vector and miR-455-5p-mimics / NC and miR-455-5p-inhibitors / NC, respectively. 36 hours after transfection, gene expression was detected by qPCR. According to the instructions of the Dual LucyAssay Kit, the luciferase activity of each well was detected using a microplate reader and normalized to the Renilla value.

[0094] The results showed that in chondrocytes and chicken embryo fibroblast cell lines, when the target region was mutated, miR-455-5p could not bind to the complementary region of the target gene to inhibit luciferase activity. Secondly, qPCR results found that RPS6KB1 expression was significantly reduced in chondrocytes treated with miR-455-5p-mimics, and significantly increased in chondrocytes treated with miR-455-5p-inhibitors (such as Fig.17 , Fig.18 , Fig.19 , Fig. 20 , Fig.21 Middle A and Fig.21 (shown in B).

[0095] VI. miR-455-5p targets RPS6KB1 to inhibit cartilage proliferation

[0096] RPS6KB1 interference fragment (siRPS6KB1) and antibodies were synthesized, and siRPS6KB1 and its siNC were used to treat chondrocytes. CCK-8 was used to detect the proliferation rate of chondrocytes at different time points; EDU was used to detect the proliferation status of chondrocytes after 36h treatment; qPCR was used to detect the expression of proliferation and metabolism-related genes Collage 2, MMP9 and MMP13 after 36h treatment; Western Blot was used to focus on detecting the expression of Collage 2 protein.

[0097] The results showed that siRPS6KB1 significantly inhibited the expression of RPS6KB1 gene in chondrocytes (e.g. Fig. 22The results of CCK-8 and EDU showed that it significantly inhibited the proliferation of chondrocytes at different time points (as shown in Fig.23 Middle A, Fig.23 Middle B, Fig.23 Middle C, Fig.23 Middle D, Fig.23 Middle E, Fig.23 Medium F, Fig.23 Medium G and Fig. 27 qPCR results showed that the expression of Collage 2 and MMP13 genes were upregulated (as shown in Fig.24 ); Western Blot results showed that the expression of RPS6KB1 and Collage 2 proteins was significantly downregulated (as shown in Fig.25 The combined results showed that siRPS6KB1 inhibited the synthesis of chondrocyte proliferation-related proteins.

[0098] Chondrocytes were treated with siRPS6KB1 / NC, miR-455-5p-mimics / NC, and miR-455-5p-inhibitors / NC. Western Blot was used to detect the downstream RPS6 and its phosphorylation level of RPS6KB1.

[0099] The results showed that siRPS6KB1 and miR-455-5p-mimics significantly inhibited RPS6 and its phosphorylation, while miR-455-5p-inhibitors promoted RPS6 and its phosphorylation (e.g. Fig.26 Middle A, Fig.26 Middle B, Fig.26 Middle C and Fig.26 (shown in D).

[0100] The specific embodiments of the present invention are described in detail above. Based on the above various verification experiments, it can be seen that the exosome miR-455-5p provided by the present invention can inhibit RPS6 and its phosphorylation level by targeting RPS6KB1, thereby inhibiting cartilage proliferation. In the early stage of the present invention, the key miR-455-5p related to cartilage development was located through deep sequencing of plasma exosome miRNA. The present invention further conducts in-depth research on how plasma exosome miR-455-5p regulates cartilage development. The present invention discloses for the first time the abnormal characteristics of cartilage development in varus and valgus deformity of broiler limbs and the expression level of miR-455-5p cartilage; it is clear that plasma exosomes can transfer miR-455-5p to chondrocytes, and combined with miR-455-5p in vitro experiments, it is comprehensively proved that it can inhibit cartilage growth and development. The present invention discloses the key regulatory target gene RPS6KB1 of miR-455-5p and confirms the targeting relationship between the two. The present invention designs siRPS6KB1 and explores that RPS6KB1 reduces the synthesis of key proteins in chondrocytes by inhibiting RPS6 phosphorylation. Therefore, the present invention explores the specific mechanism by which plasma exosome-derived miR-455-5p regulates the development of varus-valgus deformity cartilage in broiler limbs. The plasma exosome miR-455-5p regulatory axis disclosed in the present invention is of great significance in treating the abnormal development of articular cartilage in varus-valgus deformity in broiler limbs.

[0101] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. The application of microRNA-455-5p in the preparation of a kit for detecting varus-valgus deformity of broiler limbs, characterized in that: The nucleotide sequence of the microRNA-455-5p is shown in SEQ ID NO.

1.

2. The application according to claim 1, characterized in that: The microRNA-455-5p inhibits the expression of RPS6KB1 gene, inhibits the phosphorylation of RPS6, and further inhibits the synthesis of type II collagen and the proliferation of articular chondrocytes.

3. The application according to claim 2, characterized in that: The nucleotide sequence of the RPS6KB1 gene is shown in SEQ ID NO.

2.

4. A kit for detecting broiler limb valgus and valgus deformity using the microRNA-455-5p described in claim 1 as a diagnostic marker.

5. Use of microRNA-455-5p as claimed in claim 1 in preparing an inhibitor of RPS6KB1 gene expression.

6. A RPS6KB1 gene expression inhibitor, characterized in that The RPS6KB1 gene expression inhibitor comprises the microRNA-455-5p described in claim 1.

7. Use of microRNA-455-5p as claimed in claim 1 in the preparation of an inhibitor of articular chondrocyte proliferation.

8. An articular chondrocyte proliferation inhibitor, characterized in that The articular chondrocyte proliferation inhibitor comprises the microRNA-455-5p described in claim 1.

9. Use of an agent for inhibiting the expression of microRNA-455-5p as claimed in claim 1 in the preparation of an agent for treating limb valgus and valgus deformity in broiler chickens.

10. Use of an agent for inhibiting the expression of microRNA-455-5p as claimed in claim 1 in the preparation of an agent for promoting the proliferation of articular chondrocytes.

Citation Information

Patent Citations

  • MicroRNA inhibitor capable of inhibiting SOCS3 down-regulation and preparation method thereof

    CN113528525A

  • UCP1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis

    US20130331440A1

  • Prediction of preeclampsia using microrna

    US20160369343A1

  • High throughput method and system for in vivo screening

    WO2011005094A1